Mark Johns, MD
Hematology & Oncology · Cincinnati, OHNPI 1407040884
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.9%), other and education — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Novartis at 48.2% of the total.
Across 62 payments — averaging $49.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- AstraZeneca$237
- Pfizer$157
- Janssen Scientific Affairs, LLC$147
- Astellas Pharma US Inc$124
- Merck$124
- plus $785 from 16 others
Across 1,826 payments — averaging $545.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biontech SE$270K
- F. Hoffmann-la Roche AG$214K
- Genentech, Inc.$179K
- Eisai Inc.$157K
- E.r. Squibb & Sons, L.L.C.$65K
- Merck$40K
- plus $71K from 7 others
What the payments were for
- Food & beverage$1,57952%
- Education$1836%
- Other$1,28042%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 24 | $1,467 |
| AstraZeneca | 6 | $237 |
| Pfizer | 11 | $157 |
| Janssen Scientific Affairs, LLC | 1 | $147 |
| Astellas Pharma US Inc | 1 | $124 |
| Merck | 1 | $124 |
| Progenics Pharmaceuticals, Inc. | 1 | $121 |
| Bioprotect Medical, Inc. | 1 | $117 |
| Johnson & Johnson | 2 | $116 |
| Myriad Genetic Laboratories, Inc. | 1 | $109 |
| Foundation Medicine, Inc. | 1 | $80 |
| AbbVie | 2 | $54 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $30 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $14 |
| Gilead | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,041 in reported general payments places this provider in the 55th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 107 | $1,597,376 |
| Lenalidomide | 31 | $524,030 |
| QinlockRipretinib | 11 | $457,839 |
| VerzenioAbemaciclib | 20 | $297,791 |
| TasignaNilotinib Hcl | 12 | $237,370 |
| IbrancePalbociclib | 14 | $220,052 |
| ImbruvicaIbrutinib | 12 | $196,346 |
| Everolimus | 14 | $141,891 |
| Abiraterone Acetate | 36 | $141,718 |
| EliquisApixaban | 165 | $126,404 |
| XareltoRivaroxaban | 18 | $20,676 |
| Anastrozole | 613 | $6,708 |
| Oxycodone Hcl | 148 | $5,197 |
| Prochlorperazine Maleate | 124 | $3,907 |
| Ondansetron Hcl | 135 | $3,445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $237 | $1,597,376107 claims |
| PfizerIbrance, Eliquis | $157 | $346,456179 claims |
| NovartisTasigna | $1,467 | $237,37012 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $30 | $196,34612 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $147 | $141,71836 claims |
| Johnson & JohnsonXarelto | $116 | $20,67618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Cincinnati
- David WaterhouseCincinnati$1.3M
- Mark AndolinaCincinnati$402K
- James EssellCincinnati$214K
- Akash MukherjeeCincinnati$132K
- Davendra SohalCincinnati$112K
- Edward FaberCincinnati$72K
- Alexander StarodubCincinnati$72K
- Brittaney Belle GordonCincinnati$53K
- Soumit BasuCincinnati$46K
- Trisha Wise-DraperCincinnati$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.